Literature DB >> 11268986

Palliative gastrectomy for advanced gastric cancer.

K Hanazaki1, H Sodeyama, Y Mochizuki, J Igarashi, S Yokoyama, Y Sode, M Wakabayashi, N Kawamura, T Miyazaki.   

Abstract

BACKGROUND/AIMS: Although palliative gastrectomy for advanced gastric cancer may be favorable in selected patients presenting with bleeding and obstruction, little has been reported about the clinical significance of palliative gastrectomy, including prognosis.
METHODOLOGY: A retrospective comparison between 84 patients with palliative gastrectomy (PG group) and 100 patients with unresectable operation (UO group) for advanced gastric cancer was carried out.
RESULTS: The incidence of serosal invasion, peritoneal dissemination, hepatic and lymph node metastases, and undifferentiated tissue type in the UO group were significantly higher than in the PG group. Median survival after operation in the PG group (20.6 months) was significantly longer than in the UO group (5.7 months). Also, in stage IVb patients, median survival time in the PG group (10.2 months) was significantly longer than in the UO group (5.0 months). However, median survival in the patients with synchronous liver metastasis between PG (8.4 months) and UO (4.6 months) groups was not significantly different. Survival rates after operation of 6 months, 1 year and 2 years in all patients between the palliative gastrectomy group versus UO group were 83.6% versus 38.3% (P < 0.01), 63.0% versus 9.3% (P < 0.01) and 35.2% versus 0% (P < 0.01), respectively.
CONCLUSIONS: Palliative gastrectomy compared to unresectable operation may be effective for improvement of prognosis even if stage IVb patients with peritoneal dissemination and/or distant lymph node metastasis. However, it may be unfavorable on survival of patients with synchronous liver metastasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11268986

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  11 in total

Review 1.  Surgical palliation in advanced disease: recent developments.

Authors:  Geoffrey P Dunn
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

Review 2.  A systematic review of surgery for non-curative gastric cancer.

Authors:  Alyson L Mahar; Natalie G Coburn; Simron Singh; Calvin Law; Lucy K Helyer
Journal:  Gastric Cancer       Date:  2011-10-28       Impact factor: 7.370

3.  Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma.

Authors:  Abeezar I Sarela; Thomas J Miner; Martin S Karpeh; Daniel G Coit; David P Jaques; Murray F Brennan
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

4.  Is there a role for palliative gastrectomy in patients with stage IV gastric cancer?

Authors:  Reza F Saidi; Stephen G ReMine; Paul S Dudrick; Nader N Hanna
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

5.  Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery.

Authors:  Shinji Shinohara; Daisuke Korenaga; Ai Edagawa; Kenichi Koushi; Shinji Itoh; Hirofumi Kawanaka; Daihiko Eguchi; Katsumi Kawasaki; Toshiro Okuyama; Yasuharu Ikeda; Kenji Takenaka
Journal:  Surg Today       Date:  2012-06-29       Impact factor: 2.549

6.  Clinicopathological analysis of Borrmann type IV gastric cancer.

Authors:  Jeong Hwan Yook; Sung Tae Oh; Byung Sik Kim
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

7.  Palliation of metastatic gastric cancer: impact of preoperative symptoms and the type of operation on survival and quality of life.

Authors:  Volker Kahlke; Beate Bestmann; Andreas Schmid; Julius Marek Doniec; Thomas Küchler; Bernd Kremer
Journal:  World J Surg       Date:  2004-03-17       Impact factor: 3.352

8.  The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer.

Authors:  Ming-ming He; Dong-sheng Zhang; Feng Wang; Zhi-qiang Wang; Hui-yan Luo; Ying Jin; Xiao-li Wei; Rui-hua Xu
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

9.  Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery.

Authors:  Yan Liu; Ye Feng; Yongjian Gao; Ruizhi Hou
Journal:  Onco Targets Ther       Date:  2016-03-07       Impact factor: 4.147

10.  Non-curative surgery for patients with gastric cancer with local peritoneal metastasis: A retrospective cohort study.

Authors:  Yuanqiang Dong; Shulan Ma; Shuo Yang; Fen Luo; Zhiming Wang; Fenghua Guo
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.